|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM213858827 |
| 003 |
DE-627 |
| 005 |
20231224022423.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2012 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2011.10.009
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0713.xml
|
| 035 |
|
|
|a (DE-627)NLM213858827
|
| 035 |
|
|
|a (NLM)22169811
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Xu, Rende
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Kv1.3 channels as a potential target for immunomodulation of CD4+ CD28null T cells in patients with acute coronary syndrome
|
| 264 |
|
1 |
|c 2012
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.04.2012
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a CommentIn: Clin Immunol. 2012 Feb;142(2):105-6. - PMID 22189042
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2011 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Modulation of CD4(+)CD28null T cells through K+ channels could provide potential novel targets for the treatment acute coronary syndrome (ACS). However, the surface phenotype and K+ channel expression of CD4(+)CD28null T cells in patients with ACS is unclear. The aim of this study was to investigate the surface phenotype and K+ channel expression of CD4(+)CD28null T cells in patients with ACS. We found that more than 80% of CD4(+)CD28null T cells in patients with ACS showed a CD45RA(-)CD45RO(+)CCR7- surface phenotype. CD4(+)CD28(null) T expressed small numbers of the voltage-gated Kv1.3 and intermediate-conductance Ca2+-activated K+ channel KCa3.1 when quiescent, but increased Kv1.3 expression 4-fold with little change in KCa3.1 levels upon activation. Consistent with their channel phenotypes, the production of interferon-γ and perforin in CD4(+)CD28null T cells was suppressed by the specific Kv1.3 blocker 5-(4-phenoxybutoxy)psoralen PAP-1. Therefore, selective targeting of Kv1.3 in CD4(+)CD28null T cells may hold potential therapeutic promise for ACS
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a 5-(4-phenylbutoxy)psoralen
|2 NLM
|
| 650 |
|
7 |
|a CD28 Antigens
|2 NLM
|
| 650 |
|
7 |
|a Kv1.3 Potassium Channel
|2 NLM
|
| 650 |
|
7 |
|a Pancreatitis-Associated Proteins
|2 NLM
|
| 650 |
|
7 |
|a Potassium Channels, Calcium-Activated
|2 NLM
|
| 650 |
|
7 |
|a REG3A protein, human
|2 NLM
|
| 650 |
|
7 |
|a Perforin
|2 NLM
|
| 650 |
|
7 |
|a 126465-35-8
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 650 |
|
7 |
|a Ficusin
|2 NLM
|
| 650 |
|
7 |
|a KTZ7ZCN2EX
|2 NLM
|
| 700 |
1 |
|
|a Cao, Ming
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Xiaofen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Xingfen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ruan, Lei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Quan, Xiaoqing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lü, Caixia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a He, Wei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Cuntai
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 142(2012), 2 vom: 14. Feb., Seite 209-17
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:142
|g year:2012
|g number:2
|g day:14
|g month:02
|g pages:209-17
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2011.10.009
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 142
|j 2012
|e 2
|b 14
|c 02
|h 209-17
|